Fisher Asset Management LLC increased its stake in Bristol-Myers Squibb Co. (NYSE:BMY) by 0.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 650,332 shares of the biopharmaceutical company’s stock after buying an additional 2,225 shares during the period. Fisher Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $35,066,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. WESPAC Advisors SoCal LLC increased its position in Bristol-Myers Squibb by 5.1% in the second quarter. WESPAC Advisors SoCal LLC now owns 1,538 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 75 shares during the period. Acropolis Investment Management LLC increased its position in Bristol-Myers Squibb by 21.3% in the third quarter. Acropolis Investment Management LLC now owns 2,815 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 495 shares during the period. Jolley Asset Management LLC increased its position in Bristol-Myers Squibb by 4.0% in the second quarter. Jolley Asset Management LLC now owns 2,092 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 80 shares during the period. Harel Insurance Investments & Financial Services Ltd. bought a new position in Bristol-Myers Squibb during the second quarter valued at approximately $163,000. Finally, Solaris Asset Management LLC increased its position in Bristol-Myers Squibb by 3.5% in the second quarter. Solaris Asset Management LLC now owns 2,244 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 75 shares during the period. Institutional investors and hedge funds own 68.84% of the company’s stock.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb Co. (NYSE:BMY) traded down 0.20% on Wednesday, hitting $56.25. The stock had a trading volume of 1,200,239 shares. Bristol-Myers Squibb Co. has a 12-month low of $49.03 and a 12-month high of $77.12. The company has a market capitalization of $94.01 billion, a PE ratio of 28.14 and a beta of 0.90. The company has a 50 day moving average of $52.72 and a 200 day moving average of $62.87.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 27th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.12. Bristol-Myers Squibb had a return on equity of 28.98% and a net margin of 18.54%. The firm earned $4.83 billion during the quarter, compared to analysts’ expectations of $4.76 billion. During the same period in the prior year, the company earned $0.39 earnings per share. The company’s quarterly revenue was up 21.0% on a year-over-year basis. On average, equities analysts expect that Bristol-Myers Squibb Co. will post $2.85 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Fisher Asset Management LLC Has $35,066,000 Stake in Bristol-Myers Squibb Co. (BMY)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be read at https://www.thecerbatgem.com/2016/11/30/fisher-asset-management-llc-has-35066000-stake-in-bristol-myers-squibb-co-bmy.html.

Several equities analysts recently commented on BMY shares. William Blair restated a “buy” rating on shares of Bristol-Myers Squibb in a research report on Wednesday, August 10th. Citigroup Inc. cut their target price on Bristol-Myers Squibb from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Tuesday, August 9th. Argus restated a “buy” rating and set a $90.00 target price on shares of Bristol-Myers Squibb in a research report on Saturday, August 13th. Leerink Swann restated a “buy” rating and set a $75.00 target price on shares of Bristol-Myers Squibb in a research report on Wednesday, September 7th. Finally, Goldman Sachs Group Inc. restated a “buy” rating on shares of Bristol-Myers Squibb in a research report on Monday, September 12th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $67.51.

In other news, Director Lamberto Andreotti sold 21,600 shares of the company’s stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $56.87, for a total transaction of $1,228,392.00. Following the completion of the transaction, the director now directly owns 334,499 shares in the company, valued at $19,022,958.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.24% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

5 Day Chart for NYSE:BMY

Receive News & Stock Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related stocks with our FREE daily email newsletter.